Oramed COO exercises options, sells 137K shares
Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock. On July 2, 2026, he exercised 50,000 stock options at $3.69 per share, receiving an equal number of common shares. On July 1, 2026, he sold 137,000 common shares at a weighted average price of $4.463 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 1,073,384 common shares and 50,000 stock options that remain outstanding.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Hexter Joshua
Role
COO & CBO
Sold
137,000 shs ($611K)
Approx. gross sale proceeds
$611K
Approx. exercise cost
$185K
Share of Position Sold
11.8%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 50,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 50,000 | $3.69 | $185K |
| Sale | Common Stock | 137,000 | $4.463 | $611K |
Holdings After Transaction:
Stock option (right to buy) — 50,000 contracts (Direct);
Common Stock — 1,073,384 shares (Direct)
Holdings Before and After:
Stock option (right to buy), 100,000 to 50,000 contracts (Direct);
Common Stock, 1,160,384 to 1,073,384 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
- F1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.7652, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3. The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019.
Key Figures
Shares sold: 137,000 shares
Sale price (weighted average): $4.463 per share
Options exercised: 50,000 options
+4 more
7 metrics
Shares sold
137,000 shares
Common Stock sale on July 1, 2026 at $4.463 average
Sale price (weighted average)
$4.463 per share
Open-market Common Stock sales on July 1, 2026
Options exercised
50,000 options
Stock options exercised into Common Stock on July 2, 2026
Option exercise price
$3.69 per share
Stock option (right to buy) conversion price
Shares held after transactions
1,073,384 shares
Direct Common Stock holdings following July 2, 2026
Options outstanding after exercise
50,000 options
Stock option balance following July 2, 2026
Option expiration date
September 12, 2029
Expiration for the reported stock option grant
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock options, expiration date
4 terms
Rule 10b5-1 trading plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"The stock options vested and became exercisable in 16 equal installments of 6,250..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
expiration date financial
"Stock option expiration date disclosed as September 12, 2029 for the derivative security."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Oramed (ORMP) COO Joshua Hexter report?
Joshua Hexter reported exercising 50,000 stock options at $3.69 per share and selling 137,000 Oramed common shares at a weighted average price of $4.463 per share. These transactions changed his direct share and option holdings.
What stock options did Oramed (ORMP) COO Joshua Hexter exercise?
He exercised 50,000 stock options with an exercise price of $3.69 per share, receiving 50,000 Oramed common shares. The footnotes explain these options vested in 16 equal installments of 6,250 shares starting November 1, 2019.
AI-generated analysis. How Rhea-AI works. Not financial advice.
